Geron (GERN) Shares Down 7.7%

Share on StockTwits

Geron Co. (NASDAQ:GERN) traded down 7.7% during mid-day trading on Friday . The stock traded as low as $1.68 and last traded at $1.69. 4,431,393 shares traded hands during trading, an increase of 34% from the average session volume of 3,303,507 shares. The stock had previously closed at $1.83.

Several equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Geron from a “hold” rating to a “buy” rating in a research report on Saturday, March 16th. ValuEngine upgraded shares of Geron from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. BTIG Research assumed coverage on shares of Geron in a research report on Tuesday, February 12th. They set a “buy” rating and a $4.00 target price for the company. Zacks Investment Research upgraded shares of Geron from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 4th. Finally, B. Riley upgraded shares of Geron from a “neutral” rating to a “buy” rating and lifted their target price for the company from $1.50 to $3.25 in a research report on Thursday, January 31st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Geron currently has a consensus rating of “Buy” and a consensus price target of $3.39.

The firm has a market capitalization of $315.00 million, a price-to-earnings ratio of -10.56 and a beta of 2.94.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.05). The firm had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.22 million. Geron had a negative net margin of 2,534.43% and a negative return on equity of 17.61%. Equities analysts anticipate that Geron Co. will post -0.34 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank purchased a new position in shares of Geron in the fourth quarter worth $25,000. IHT Wealth Management LLC purchased a new position in shares of Geron in the fourth quarter worth $37,000. HRT Financial LLC increased its stake in shares of Geron by 192.6% in the fourth quarter. HRT Financial LLC now owns 40,098 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 26,393 shares during the period. SVA Plumb Wealth Management LLC increased its stake in shares of Geron by 98.8% in the fourth quarter. SVA Plumb Wealth Management LLC now owns 50,300 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 25,000 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Geron by 99.6% in the fourth quarter. SG Americas Securities LLC now owns 56,479 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 28,181 shares during the period. Hedge funds and other institutional investors own 33.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Geron (GERN) Shares Down 7.7%” was published by Highlight Press and is owned by of Highlight Press. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://highlightpress.com/2019/03/24/geron-gern-shares-down-7-7.html.

Geron Company Profile (NASDAQ:GERN)

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Read More: Economic Reports

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.